People
Meet Our Team
Monument Tx is led by a highly experienced team of executives with direct experience designing and managing hundreds of cognitive clinical trials.
Dr Jenny Barnett
Chief Executive Officer
Jenny was Chief Scientific Officer at Cambridge Cognition where she led clinical trial, healthcare and R&D functions before spinning out Monument Therapeutics.
She has an MA in Experimental Psychology from Oxford University, a PhD in the Epidemiology of Schizophrenia from the University of Cambridge, and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She is the author of more than 70 papers, six patents, and two popular science books and is an honorary member of the University of Cambridge Department of Psychiatry.
Dr Kiri Granger
Chief Scientific Officer
Kiri is an internationally-recognised expert in the design of clinical trials for CNS disorders, particularly schizophrenia.
As Director of Neuroscience at Cambridge Cognition, Kiri provided consultancy to over 50 drug development companies on more than 100 clinical trials and was the lead scientist on a number of successful programmes. Kiri chaired the ICSTM working group on schizophrenia clinical trials and is currently an Assistant Professor at the University of Nottingham, Department of Psychology where she is involved in on-going collaborations in schizophrenia and anxiety disorders.
Sheryl Caswell
Chief Development Officer
Sheryl brings clinical development expertise from a long career working on new, reformulated and repurposed products for over twenty five years.
She has successfully led and managed global clinical development programmes across a range of therapeutic indications, with a recent focus on working in small biotech companies identifying regulatory pathways and designing and conducting development programmes of products at an early phase of development.
Dr Mark Treherne
Chair
Mark has been actively involved in the biopharmaceutical industry for over 25 years and previously led the neurodegeneration research group at Pfizer’s research facility in Sandwich.
To date he has helped to raise over £300 million for early-stage biotechnology companies and out-licensed therapeutic assets for upfront payments, milestones and royalties exceeding £1.5 billion. Mark has a PhD in Pharmacology from the University of Cambridge.
Dr Paula Moran
Scientific Consultant
Paula is a pioneering research scientist and an honorary Associate Professor at the University of Nottingham.
Following a PhD from the National University of Ireland she has had academic roles at the Institute of Psychiatry, Kings College London and University of Nottingham, where she led collaborations with several pharmaceutical industry partners. She is best known for her translational research on abnormal information processing.
Dr Julian Gilbert
Non-Exec Director
Julian brings deep expertise in the development and commercialising of repurposed compounds, having been co-founder and CEO of Acacia Pharma.
Julian was previously co-founder and Commercial Director of Arakis, and has 30 years of commercial and technical experience gained at Chiroscience, Mundipharma International, BTG and GSK. Julian holds a degree in Pharmacy and a PhD in Pharmaceutics from the University of Nottingham.
Richard Bungay
Non-Exec Director
Richard is currently Chief Executive Officer at Imophoron.
He has over 25 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector, including executive roles at Mereo BioPharma, Glide Technologies, Verona Pharma, of Chroma Therapeutics, and Celltech. Richard is a Non-Executive Director of Cambridge Cognition. He qualified as a Chartered Accountant with Deloitte and has a first class degree in Chemistry from Nottingham University.
Steve Plant
CFO
Steve is an experienced Finance Director specialising in working with early-stage SMEs in the UK tech/healthcare sector.
He qualified as a Chartered Accountant in Manchester with KPMG and after qualifying joined a UK-wide retail business where he held a number of roles. He then moved into international retail as finance director for new business start-ups in Russia and India. On returning to the UK Steve has held a variety of Financial Director roles in customer facing businesses across a broad range of industry sectors.
Sheryl Caswell
Chief Development Officer
Sheryl brings clinical development expertise from a long career working on new, reformulated and repurposed products for over twenty five years.
She has successfully led and managed global clinical development programmes across a range of therapeutic indications, with a recent focus on working in small biotech companies identifying regulatory pathways and designing and conducting development programmes of products at an early phase of development.
Dr Mark Treherne
Chair
Mark has been actively involved in the biopharmaceutical industry for over 25 years and previously led the neurodegeneration research group at Pfizer’s research facility in Sandwich.
To date he has helped to raise over £300 million for early-stage biotechnology companies and out-licensed therapeutic assets for upfront payments, milestones and royalties exceeding £1.5 billion. Mark has a PhD in Pharmacology from the University of Cambridge.
Dr Paula Moran
Scientific Consultant
Paula is a pioneering research scientist and an honorary Associate Professor at the University of Nottingham.
Following a PhD from the National University of Ireland she has had academic roles at the Institute of Psychiatry, Kings College London and University of Nottingham, where she led collaborations with several pharmaceutical industry partners. She is best known for her translational research on abnormal information processing.
Dr Julian Gilbert
Non-Exec Director
Julian brings deep expertise in the development and commercialising of repurposed compounds, having been co-founder and CEO of Acacia Pharma.
Julian was previously co-founder and Commercial Director of Arakis, and has 30 years of commercial and technical experience gained at Chiroscience, Mundipharma International, BTG and GSK. Julian holds a degree in Pharmacy and a PhD in Pharmaceutics from the University of Nottingham.
Richard Bungay
Non-Exec Director
Richard is currently Chief Executive Officer at Imophoron.
He has over 25 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector, including executive roles at Mereo BioPharma, Glide Technologies, Verona Pharma, of Chroma Therapeutics, and Celltech. Richard is a Non-Executive Director of Cambridge Cognition. He qualified as a Chartered Accountant with Deloitte and has a first class degree in Chemistry from Nottingham University.
Steve Plant
CFO
Steve is an experienced Finance Director specialising in working with early-stage SMEs in the UK tech/healthcare sector.
He qualified as a Chartered Accountant in Manchester with KPMG and after qualifying joined a UK-wide retail business where he held a number of roles. He then moved into international retail as Finance Director for new business start-ups in Russia and India. On returning to the UK Steve has held a variety of Financial Director roles in customer facing businesses across a broad range of industry sectors.
Meet Our Advisory Board
Monument Tx’s Advisory Board is comprised of a highly experienced team of scientific professionals with a wide range of experience across the pharmaceutical and biotechnology sectors.
Dr Robin Bannister
A successful drug development entrepreneur who focuses on the discovery of novel biology based on existing drugs.
Professor Ed Bullmore
Head of the Department of Psychiatry, University of Cambridge. Ed has authored more than 500 publications, has 15 years’ experience in the pharmaceutical industry and is the author of “The Inflamed Mind.”
Dr Robert Gristwood
Founder and Chief Scientist at Acacia Pharma. Robert has worked within the pharmaceutical industry for more than 30 years’ and been responsible for many innovative products.
Fiona Cree
Fiona is COO of Cambridge Cognition and leads the Clinical Science and Operations teams there. She has 25 years’ experience in multi-national pharmaceutical companies and biotech SMEs, including a biotech focusing on development of a drug and diagnostic for Alzheimer’s disease.
Dr Steven Powell
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over thirty years operational and investment experience in pharmaceutical and healthcare companies in the UK, USA and Scandinavia.
Dr Ann Hayes
Consultant to the pharmaceutical industry with many years’ experience of the pharmaceutical / biotechnology / digital health industry.
Professor Trevor Robbins
Professor of Cognitive Neuroscience and former Head of the Department of Psychology at the University of Cambridge.
Dr Stephen Wright
Consultant in Drug Development,
previously CMO, Head of R&D and main Board Director at GW Pharma, and Sen VP of Development and Board Director of Ipsen.
Dr CD Nigel Toseland
Toxicological pathologist and fellow of the Royal College of Pathologists with over 30 years’ experience in the pharmaceutical industry. Broad therapeutic experience advising companies on pre-clinical development, expert toxicology overviews and conducting due diligence for licensing activities.
Dr Michael Sand
Michael has 35 years’ experience in the pharmaceutical industry, focused on developing novel compounds for serious mental illness. He currently serves as an Independent Consultant to the NIMH.
Fiona Cree
Fiona is COO of Cambridge Cognition and leads the Clinical Science and Operations teams there. She has 25 years’ experience in multi-national pharmaceutical companies and biotech SMEs, including a biotech focusing on development of a drug and diagnostic for Alzheimer’s disease.
Dr Steven Powell
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over thirty years operational and investment experience in pharmaceutical and healthcare companies in the UK, USA and Scandinavia.
Dr Ann Hayes
Consultant to the pharmaceutical industry with many years’ experience of the pharmaceutical / biotechnology / digital health industry.
Professor Trevor Robbins
Professor of Cognitive Neuroscience and former Head of the Department of Psychology at the University of Cambridge.
Dr Stephen Wright
Consultant in Drug Development,
previously CMO, Head of R&D and main Board Director at GW Pharma, and Sen VP of Development and Board Director of Ipsen.
Dr CD Nigel Toseland
Toxicological pathologist and fellow of the Royal College of Pathologists with over 30 years’ experience in the pharmaceutical industry. Broad therapeutic experience advising companies on pre-clinical development, expert toxicology overviews and conducting due diligence for licensing activities.
Dr Michael Sand
Michael has 35 years’ experience in the pharmaceutical industry, focused on developing novel compounds for serious mental illness. He currently serves as an Independent Consultant to the NIMH.
Contact Us
We believe that neuroscience will be in the next decade what oncology has been in the last.
